

# Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19

Yahya Shaikh, MD, MPH<sup>\*1</sup> and Ishaan Gupta, MBBS<sup>\*2</sup>, Sophia Purekal, MD<sup>3</sup>, Mary Jane E. Vaeth, BS<sup>3</sup>, Maisha Foyez, GED<sup>3</sup>, Charles D. Callahan, DO<sup>4</sup>, Maryam Elhabashy, BA<sup>5</sup>, James R. Ficke, MD<sup>6</sup>, Albert W. Wu, MD, MPH<sup>7</sup>, Paul G. Auwaerter, MD, MBA<sup>8</sup>, Melinda E. Kantsiper, MD<sup>2</sup>, Zishan K. Siddiqui, MD, MBA<sup>9</sup>

\*These authors contributed equally

1. MITRE Corporation, Baltimore, Maryland, USA
2. Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3. Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA
4. Department of Population Health, University of Maryland Medical Center, Baltimore, Maryland, USA
5. University of Maryland, Baltimore County, Maryland, USA
6. Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA
7. Department of Medicine, General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

8. The Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases,  
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
9. Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

**Running title:** Racial Disparities in COVID-19 mAb use

**Abstract word count:** 97 words

**Manuscript word count:** 1159 words

**Corresponding author:**

Ishaan Gupta MD

Johns Hopkins Bayview Medical Center

5200 Eastern Avenue

MFL East Tower, Room 260

Baltimore MD 21224

Phone: 410-550-5018

Fax No:

Email: [igupta4@jhmi.edu](mailto:igupta4@jhmi.edu)

## Abstract

**Background and Methods:** We conducted a single center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021 and May 14, 2021.

**Results:** Among the 2,406 eligible participants, African Americans were significantly more likely to underutilize mAb treatment (OR 1.8; 95% CI 1.5-2.1) and miss treatment opportunities due to monoclonal hesitancy (OR 1.7, 95% CI 1.3-2.1).

**Conclusion:** Addressing racial disparities in mAb delivery is an opportunity to bridge the racial inequities in COVID-19 care.

**Keywords:** Disparities, Utilization, Equity, Monoclonal Antibody, Hesitancy, COVID-19

## 1 Background

2 Since the start of the COVID-19 pandemic, members of racial and ethnic minorities  
3 have borne a disproportionate burden of disease with disparities in infection rates,  
4 hospitalization, and death.<sup>1,2</sup> Further, differences have also been seen in preventive  
5 measures, with African-Americans expressing a rate of vaccine hesitancy three times  
6 greater than whites.<sup>3</sup> Targeted interventions to address barriers and improve equity in  
7 COVID-19 outcomes have included uptake of vaccines.<sup>4,5</sup> However, whether access to  
8 highly effective monoclonal antibody (mAb) infusions for the treatment of COVID-19  
9 face similar issues is unknown.

10 Three anti-SARS-CoV-2 monoclonal antibody products have received Emergency Use  
11 Authorizations (EUAs) from the Food and Drug Administration (FDA) to treat mild to  
12 moderate COVID-19 in non-hospitalized patients at high risk for progressing to severe  
13 disease and/or hospitalization. These have been shown to improve outcomes.<sup>6</sup> We  
14 investigated if there is evidence for racial disparities in utilization of mAb and treatment  
15 hesitancy after referral to a high-volume infusion site.

16

## 17 Methods

18 This was a cross-sectional analysis of patients seen at the mAb infusion site linked to  
19 the Baltimore Convention Center Field Hospital (BCCFH), Maryland's largest infusion  
20 site. The operational structure for BCCFH has been described.<sup>7</sup> All patients referred to  
21 the center from January 4<sup>th</sup>, 2021 to May 14<sup>th</sup>, 2021, who were eligible to receive mAb

22 treatment based on their disease severity and risk factors, were included in the study.  
23 Patients were referred by community providers using a web-based form that  
24 automatically populated the scheduling spreadsheet. Treatment was provided with no  
25 out-of-pocket payment irrespective of insurance status. Free transportation was offered  
26 to and from the infusion center. Patients outside of the 10-day eligibility period were  
27 excluded and marked as "Timed Out." Attempts were made to contact eligible patients  
28 within 24 hours to schedule a treatment. Additional attempts were made, and the  
29 referring provider was contacted via automated email after two failed attempts. The  
30 disposition status of the patient was documented after each contact attempt (e.g.,  
31 "Unable to be Reached," "Declined," "Cancelled," "Hospitalized," "Treated Elsewhere,"  
32 "Scheduled"). The scheduled patient's status was updated on the planned infusion date  
33 ("No-Show," "ED-transfer after Arrival," "Treated"). Final disposition status of "Refused  
34 Treatment" or "Cancelled" was categorized as mAb hesitancy partly because further  
35 inquiry often revealed doubts about the treatment. Treatment at BCCFH or elsewhere  
36 was categorized "Appropriate Utilization." All other disposition statuses of referred  
37 patients and eligible patients that did not lead to treatment were considered  
38 "Underutilization."

39 Racial disparities were assessed using logistic regression models to compare odds by  
40 race for treatment utilization, final disposition status, overall underutilization, and  
41 disposition consistent with mAb hesitancy. All analyses were conducted as both  
42 unadjusted models and models adjusted for gender, age, and poverty rate using the  
43 patient's zip code of residence as a surrogate for socioeconomic status derived from the  
44 American Community Survey.<sup>8</sup> All statistical testing was 2-tailed with an  $\alpha = .05$  using

45 SAS Studio Software, Version 3.8 of SAS (SAS Institute Inc., Cary, NC, USA). The  
46 study was approved by local institutional review board. The dataset is not publicly  
47 available.

## 48 Results

49 Between 1/04/2021 and 05/14/2021, 2406 eligible patients were referred, of which  
50 57.4% (1382) were white, 35% (841) were African American, 3.4% were Latinx, 3.1%  
51 Asian, with Native Americans, Pacific Islanders, and self-identified categories making up  
52 less than 1%. African American patients were younger, with a mean age of 54.6 (95%  
53 CI, 53.6-55.6) vs. 61.3 years (95% CI, 60.5-62.1) for whites, and were more often from  
54 neighborhoods with higher levels of poverty (Table 1). Overall, 69.5% (95% CI, 67.6-  
55 71.3) of referred patients were treated at BCCFH, with a greater proportion of whites  
56 receiving mAb (74% [95% CI, 71.7-76.3]) vs African American (63.8% [95%CI, 60.5-  
57 67.0]).

58 Among referred patients, 12.6% (95% CI, 10.3-14.8) of African Americans and 8.0%  
59 (95% CI, 6.5-9.4) of whites refused treatment; and 8.7% (95% CI, 6.8-10.6) of African  
60 Americans and 4.5% of whites (95% CI, 3.4-5.6) were unreachable. (Figure 1) Overall,  
61 mAb hesitancy accounted for 48.0% (95% CI, 44.3-51.7) of underutilization.

62 Compared to whites, African-Americans had 3.5 (95% CI, 1.4-8.8) times greater odds of  
63 being transferred to the Emergency Department on arrival to infusion site; 2.0 times  
64 greater odds (95% CI, 1.4-2.9) of being unreachable during the 10-day eligibility window  
65 for mAb treatment; and 1.7 times greater odds (95% CI, 1.3-2.2) of refusing treatment.

66 African Americans had greater odds of under-utilizing mAb infusion treatment (1.8; 95%  
67 CI: 1.5, 2.1) and missing treatment opportunities because of monoclonal hesitancy (1.7;  
68 95% CI: 1.3-2.1). Whites had greater odds of being treated at BCCFH (OR 1.6; 95% CI,  
69 1.3-1.9) or another infusion site (3.2; 95% CI, 1.3-7.7). The results were similar after  
70 adjusting for age, gender and socioeconomic status (Table 2).

## 71 Discussion

72 This study of patient utilization patterns after referral for mAb reveals disparities  
73 between whites and African-Americans. This occurred despite efforts to mitigate  
74 barriers to utilization, including free transportation and zero out-of-pocket expenses.  
75 African Americans were more likely to underutilize mAb after referral. Higher rates of  
76 mAb hesitancy appear to be the main reason for underutilization. Additional factors  
77 included delays due to disease severity, requiring emergency department transfer on  
78 infusion date, inability to follow-up reliably as demonstrated by no-show rates, and  
79 failure to be contacted.

80 Compared to whites, African Americans had higher odds of underutilization and mAb  
81 hesitancy as a final disposition status. This suggests that race is a strong driver of  
82 underutilization and hesitancy in the overall referred population. Hesitancy has been  
83 cited as a reason for the low uptake of mAb treatment.<sup>9</sup> The higher prevalence of mAb  
84 hesitancy among African Americans in our population parallels patterns in COVID-  
85 19 vaccine hesitancy.<sup>10</sup> A significant cause of vaccine hesitancy for African-Americans  
86 relates to concerns about safety and efficacy,<sup>11</sup> worry that treatment may be harmful

87 with a lack of trust in COVID treatment, and distrust related to unethical historical  
88 research practices among the Blacks.<sup>12</sup> Evidence-based approaches have been used to  
89 address social, individual, and structural issues related to vaccine hesitancy.<sup>4,5</sup> A similar  
90 approach will be needed to uncover reasons for mAb hesitancy and overcome it.  
91 Hesitancy to mAb may not be as entrenched as vaccines, but this treatment may also  
92 have a different risk-benefit profile. Delays in care and loss to follow-up may be related  
93 to economic barriers, patient perceptions of their needs, and fragmentation of care.  
94 These patients may benefit if efforts to achieve equity in Covid care were expanded  
95 include to mAb treatment.

96

97 As a single-site study, the generalization of these results is limited. In addition, we may  
98 have missed patients who utilized services elsewhere. However, our site provided over  
99 a third of infusions in the state, and our study suggests that African Americans were  
100 less like to use services elsewhere. In conclusion, African Americans disproportionately  
101 underutilize anti-SARS-CoV-2 monoclonal antibody treatment despite referral.  
102 Hesitancy about mAb treatment may be the primary reason. There may be a similar  
103 problem in the community leading to non-referral. Efforts to better understand mAb  
104 hesitancy and other barriers, and proactive outreach similar to those employed for  
105 Covid-19 vaccination, may be needed to mitigate barriers for underserved communities  
106 and high-risk patients.



**Authorship confirmation statement:** All persons listed as authors meet the authorship criteria and all authors have made significant contribution in conception, design, analysis, writing and revision of the manuscript. All authors have read and approved the manuscript.

**Acknowledgements:** None

**Disclosures:** Authors do not have any conflict of interests to disclose.

**Financial Support:** This work was not supported by any financial grant.

**Meeting Presentations:** This work has not been presented at any meeting.

## References

1. Romano SD, Blackstock AJ, Taylor EV, et al. Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020. *MMWR. Morbidity and mortality weekly report* 2021;70:560-5.
2. Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. *BMJ global health* 2020;5:e002913.
3. Nguyen LH, Joshi AD, Drew DA, et al. Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake. *medRxiv : the preprint server for health sciences* 2021.
4. Grumbach K, Carson M, Harris OO. Achieving Racial and Ethnic Equity in COVID-19 Vaccination. *JAMA health forum* 2021;2:e211724.


5. Evans A, Webster J, Flores G. Partnering With the Faith-Based Community to Address Disparities in COVID-19 Vaccination Rates and Outcomes Among US Black and Latino Populations. *JAMA : the journal of the American Medical Association* 2021;326:609-10.
6. National Institute of Health. Anti-SARS-CoV-2 Monoclonal Antibodies. Available at: <https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-mono-clonal-antibodies>. Accessed 10/, 2021.
7. Jones JA, Siddiqui ZK, Callahan C, et al. Infection Prevention Considerations for a Multi-Mission Convention Center Field Hospital in Baltimore, Maryland, During the COVID-19 Pandemic. *Disaster medicine and public health preparedness* 2021:1-8.
8. U.S. Census Bureau; American Community Survey, 2015-2019 American Community Survey 5-Year Estimates, Table S1701. Retrieved from <https://data.census.gov/cedsci/table?q=poverty&g=0400000US24,24%248600000&tid=ACSSST5Y2019.S1701>; (11 October 2021).
9. Anderson TS, O'Donoghue AL, Dechen T, Mechanic O, Stevens JP. Uptake of Outpatient Monoclonal Antibody Treatments for COVID-19 in the United States: a Cross-Sectional Analysis. *Journal of general internal medicine : JGIM* 2021.
10. Momplaisir FM, Kuter BJ, Ghadimi F, et al. Racial/Ethnic Differences in COVID-19 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic Hospitals. *JAMA Network Open* 2021;4:e2121931.
11. Callaghan T, Moghtaderi A, Lueck JA, et al. Correlates and Disparities of COVID-19 Vaccine Hesitancy. *SSRN Electronic Journal*.

12. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J.

Understanding Drivers of COVID-19 Vaccine Hesitancy Among Blacks. *Clinical*

*infectious diseases* 2021

**Figure 1. Distribution of Patients Final Disposition Status Between Referral and Treatment by Race**



- Timed out: patients past 10-day window of eligibility after symptom onset at the time of referral
- Hospitalized: patients hospitalized when scheduling call was made
- Treated elsewhere: on initial call declined appointment because treated elsewhere OR called to cancel an appointment at BCCFH because treated elsewhere
- Cancelled: patients called to cancel the appointment without being scheduled elsewhere
- Transferred to ED: Patient unstable on arrival to infusion site and transferred to ED prior to any treatment

**Table 1. Patients Demographics**

	<b>Total (%) N=2406</b>	<b>African-American (%) N=841</b>	<b>White (%) N=1382</b>	<b>p-value</b>
<b>Age (years old)</b>	58.6 (58.0-59.2)	54.6 (53.6-55.6)	61.3 (60.5-62.1)	<0.0001
<b>Age Category (years old)</b>				
<55	33.1 (31.2-35.0)	44.2 (40.8,47.5)	25.3 (23.0,27.6)	<0.0001
>= 55	66.9 (65.0-68.8)	55.8 (52.5,59.2)	74.7 (72.4,77.0)	
<b>Gender</b>				
Female	56.9 (54.9-58.9)	66.6 (63.4-69.8)	51.7 (49.0-54.3)	<0.0001
Male	43.1 (41.1-45.1)	33.4 (30.2-36.6)	48.3 (45.7-51.0)	
<b>Rental Housing in Patient's Zipcode</b>				
0 – 20%	27.9 (26.1-29.7)	7.8 (6.0-9.7)	40.5 (37.9-43.1)	<0.0001
20 – 40%	42.5 (40.5-44.5)	40.4 (37.1-43.7)	42.8 (40.2-45.4)	
40%+	29.6 (27.8-31.4)	51.8 (48.4-55.2)	16.6 (14.7-18.6)	
<b>Poverty Rate in Patient's Zipcode</b>				
0 - 10%	64.5 (62.6-66.4)	39.2 (35.9-42.5)	78.8 (76.6-81.0)	<0.0001
10 - 20%	23.0 (21.3-24.7)	31.4 (28.2-34.5)	18.0 (16.0-20.0)	
20+ %	12.5 (11.2-13.8)	29.5 (26.4-32.5)	3.2 (2.3-4.1)	
<b>Baltimore City Residence</b>	39.8 (37.8-41.7)	62.6 (59.3-65.9)	27.3 (24.9-29.6)	<0.0001

Final Disposition Status of Referred Patients (%)	Unadjusted <sup>1</sup>	Adjusted <sup>1*</sup>
---	-------------------------	------------------------

Table 2. Comparison of Disposition Status by Race

	Overall	African American	White	OR (95%CI)	p-value	OR (95%CI)	P-value
<b>Appropriate Utilization (ref= African American)</b>							
Treated at BCCFH (ref= African American)	69.5 (67.6-71.3)	63.8 (60.5-67.0)	74.0 (71.7-76.3)	1.6 (1.3-1.9)	<0.0001	1.7 (1.4-2.0)	<0.0001
Treated Elsewhere <sup>a</sup> (ref= African American)	1.7 (1.2-2.2)	0.7 (0.1-1.3)	2.2 (1.5-3.0)	3.2 (1.3-7.7)	0.0091	2.8 (1.0-8.3)	0.0569
<b>Under-utilization (ref=White)</b>							
Refused Treatment (ref=White)	9.7 (8.5-10.9)	12.6 (10.3-14.8)	8.0 (6.5-9.4)	1.7 (1.3-2.2)	0.0004	1.6 (1.2-2.2)	0.0018
Cancelled Appointment <sup>b</sup> (ref=White)	4.2 (3.4-5.0)	4.2 (2.8-5.5)	3.9 (2.9-4.9)	1.1 (0.7-1.6)	0.7712	1.2 (0.8-2.0)	0.3929
Patient "No-Show" (ref=White)	1.2 (0.7-1.6)	1.8 (0.9-2.7)	0.7 (0.2-1.1)	2.8 (1.2-6.4)	0.0165	2.4 (0.9-6.4)	0.0849
Unable to be Reached (ref=White)	6.5 (5.5-7.5)	8.7 (6.8-10.6)	4.5 (3.4-5.6)	2.0 (1.4-2.9)	0.0001	1.9 (1.3-2.9)	0.0014
Hospitalized <sup>c</sup> (ref=White)	2.1 (1.5-2.7)	2.7 (1.6-3.8)	1.7 (1.0-2.3)	1.7 (0.9-3.0)	0.0897	1.7 (0.9-3.2)	0.1222
Timed out by Referral <sup>d</sup> (ref=White)	4.3 (3.5-5.1)	3.8 (2.5-5.1)	4.6 (3.5-5.7)	1.2 (0.8-1.9)	0.3921	1.1 (0.7-1.8)	0.6626
Transferred to ED (ref=White)	1.0 (0.6-1.3)	1.8 (0.9-2.7)	0.5 (0.1-0.9)	3.5 (1.4-8.8)	0.0058	3.6 (1.4-9.3)	0.0075
<b>mAb Hesitancy (ref= White)</b>	13.8 (12.5-15.2)	16.7 (14.2-19.3)	11.9 (10.2-13.6)	1.7 (1.3-2.14)	<0.0001	1.7 (1.3-2.3)	<0.0001
<b>Overall Under-Utilization (ref=African American)</b>	28.8 (27.0-30.6)	35.5 (32.3-38.7)	23.7 (21.5-26.0)	1.8 (1.5-2.1)	<0.0001	1.8 (1.5-2.2)	<0.0001

<sup>1</sup> Comparing whites and African Americans

<sup>a</sup> Treated elsewhere: on initial call declined appointment because treated elsewhere OR called to cancel appointment at BCCFH because treated elsewhere

<sup>b</sup> Cancelled: patients called to cancel appointment without being scheduled elsewhere

<sup>c</sup> Hospitalized: patients hospitalized when scheduling call was made

<sup>d</sup> Timed out by referral: patients past 10-day window of eligibility after symptom onset at time of referral

\*Adjusted for Age, Gender and Poverty Level in Patient's residential zip code